Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development. The company has collaboration agreements with Lund University, Sweden; and Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, as well as a strategic research collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RCKT
Previous Symbol
CUSIPN/A
Phone646-440-9100
Debt
Debt-to-Equity Ratio0.28
Current Ratio12.52
Quick Ratio13.27
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.61 per share
Price / Book3.95
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-29,490,000.00
Net MarginsN/A
Return on Equity-49.35%
Return on Assets-35.47%
Miscellaneous
Employees20
Outstanding Shares39,830,000
Market Cap$566.86 million
OptionableOptionable
Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions
What is Rocket Pharmaceuticals' stock symbol?
Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."
How were Rocket Pharmaceuticals' earnings last quarter?
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) released its quarterly earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.43) by $0.03. View Rocket Pharmaceuticals' Earnings History.
When is Rocket Pharmaceuticals' next earnings date?
What price target have analysts set for RCKT?
4 analysts have issued 12-month price objectives for Rocket Pharmaceuticals' shares. Their forecasts range from $27.00 to $30.00. On average, they expect Rocket Pharmaceuticals' share price to reach $28.50 in the next year. This suggests a possible upside of 100.0% from the stock's current price. View Analyst Price Targets for Rocket Pharmaceuticals.
What is the consensus analysts' recommendation for Rocket Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rocket Pharmaceuticals.
What are Wall Street analysts saying about Rocket Pharmaceuticals stock?
Here are some recent quotes from research analysts about Rocket Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States. " (11/16/2018)
- 2. William Blair analysts commented, "Rocket Pharmaceuticals, Inc. We are initiating coverage of Outperform rating and $32 fair value estimate. Rocket is a multi-platform biotechnology company that is focused on developing irst-in-class gene thera pies for rare dis- eases. The company’s lead candidate, RP-L102, is an ex vivo lentiviral gene therapy being developed for the treatment of Fanconi anemia (FA), with three additional ex vivo lentivirus programs in earlier development for the treatment of leukocyte adhesion deiciency-I (LAD-I), pyruvate kinase deiciency (PKD) , and infantile malignant osteopetrosis (IMO). We also expect the company to disclose its in vivo adeno-associated virus (AAV) gene therapy indication by year end, as the company anticipates having up to four programs in the clinic (likely and data from two (likely FA, LAD-I) in 2019. Plat- form and Longer Follow-Up." (7/10/2018)
Has Rocket Pharmaceuticals been receiving favorable news coverage?
Media headlines about RCKT stock have been trending very positive on Saturday, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Rocket Pharmaceuticals earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Rocket Pharmaceuticals' key competitors?
Some companies that are related to Rocket Pharmaceuticals include Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), ACADIA Pharmaceuticals (ACAD), Myokardia (MYOK), Heron Therapeutics (HRTX), Xencor (XNCR), Prestige Consumer Healthcare (PBH), Pacira Pharmaceuticals (PCRX), Amicus Therapeutics (FOLD), Endocyte (ECYT), Global Blood Therapeutics (GBT), Opko Health (OPK), Reata Pharmaceuticals (RETA), AnaptysBio (ANAB) and Ironwood Pharmaceuticals (IRWD).
Who are Rocket Pharmaceuticals' key executives?
Rocket Pharmaceuticals' management team includes the folowing people:
- Mr. Gaurav Shah, CEO, Pres & Director
- Mr. John C. Militello, Principal Financial & Accounting Officer and Controller (Age 45)
- Ms. Kinnari Patel PharmD, MBA, Chief Operating Officer & Head of Devel.
- Dr. Claudine Prowse Ph.D., Sr. VP Corp. Devel. & IRO
- Mr. Jonathan Schwartz M.D., Chief Medical Officer and Head of Clinical Devel.
Who are Rocket Pharmaceuticals' major shareholders?
Rocket Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.70%), FMR LLC (2.70%), AXA (0.32%), Bank of New York Mellon Corp (0.20%), Alps Advisors Inc. (0.18%) and Renaissance Technologies LLC (0.17%). Company insiders that own Rocket Pharmaceuticals stock include David P Southwell and Naveen Yalamanchi. View Institutional Ownership Trends for Rocket Pharmaceuticals.
Which institutional investors are selling Rocket Pharmaceuticals stock?
RCKT stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Wells Fargo & Company MN, Alliancebernstein L.P., Virtus ETF Advisers LLC, Credit Suisse AG, TIAA CREF Investment Management LLC, JPMorgan Chase & Co. and Monarch Partners Asset Management LLC. View Insider Buying and Selling for Rocket Pharmaceuticals.
Which institutional investors are buying Rocket Pharmaceuticals stock?
RCKT stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., AXA, MetLife Investment Advisors LLC, Alps Advisors Inc., Essex Investment Management Co. LLC, Man Group plc and Bank of New York Mellon Corp. View Insider Buying and Selling for Rocket Pharmaceuticals.
How do I buy shares of Rocket Pharmaceuticals?
Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rocket Pharmaceuticals' stock price today?
One share of RCKT stock can currently be purchased for approximately $14.25.
How big of a company is Rocket Pharmaceuticals?
Rocket Pharmaceuticals has a market capitalization of $566.86 million. Rocket Pharmaceuticals employs 20 workers across the globe.
What is Rocket Pharmaceuticals' official website?
How can I contact Rocket Pharmaceuticals?
Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected]
MarketBeat Community Rating for Rocket Pharmaceuticals (NASDAQ RCKT)
MarketBeat's community ratings are surveys of what our community members think about Rocket Pharmaceuticals and other stocks. Vote "Outperform" if you believe RCKT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCKT will underperform the S&P 500 over the long term. You may vote once every thirty days.
